9 October 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Issue of Equity and Total Voting Rights
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Financial Officer, has exercised options over 14,782 ordinary shares of 5 pence each ("Ordinary Shares") at a price of 5 pence per Ordinary Share under the Company's Deferred Bonus Scheme. These share options were issued to Mr Wilks on 24 September 2021 as one-third of his bonus award for the year ended 31 March 2021 and were subject to a three year vesting period in accordance with the rules of the scheme.
Following this transaction, Christopher Wilks' total interest in the Company is 173,877 Ordinary Shares, representing approximately 0.26 per cent. of the Company's issued share capital.
Application has been made to the London Stock Exchange for 14,782 new Ordinary Shares to be admitted to trading on AIM. Admission and dealings in the new Ordinary Shares is expected to occur at 8.00 a.m. on 15 October 2024.
The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Total Voting Rights
Following Admission, the Company's total issued share capital will consist of 67,759,671 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 67,759,671.
The above figure of 67,759,671 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Christopher Wilks |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
ECO Animal Health Group plc |
|||
|
b)
|
LEI
|
2138009XN9DJ3YP70B55 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of 5 pence each
|
|||
|
|
|
||||
|
Identification code |
GB0032036807 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Exercise of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
5 pence
|
14,782 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
N/A - Single transaction |
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
7 October 2024
|
|||
|
f)
|
Place of the transaction
|
Off Market |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
